Stock ENLV ENLIVEX THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Delayed Nasdaq
Other stock markets
 19:22:45 15/05/2024 BST 		5-day change 1st Jan Change
1.417 USD -2.29% Intraday chart for Enlivex Therapeutics Ltd. -8.59% -47.53%
04-22 Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial MT
04-22 Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Enlivex Therapeutics : Report of Periodic or Interim Report
PU
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
AQ
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
GL
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
GL
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
GL
Enlivex Therapeutics : Notes to Consolidated Financial Statements - Form 6-K
PU
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
GL
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
AQ
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
GL
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
AQ
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
GL
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
PU
Enlivex Therapeutics : Purchase Agreement - Form 6-K
PU
Enlivex Therapeutics : Annual General Meeting of Shareholders - Form 6-K
PU
Enlivex Therapeutics : Annual General Meeting of Shareholders - Form 6-K
PU
Enlivex Therapeutics : Report Of Foreign Private Issuer - Form 6-K
PU
Enlivex Therapeutics : Immediate Report of Meeting
PU
ENLIVEX THERAPEUTICS : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENLV Stock
  4. News Enlivex Therapeutics Ltd.
  5. Press Releases